Caris Life Sciences Inc., of Irving, Texas, said a study published in Cancer Epidemiology, Biomarkers & Prevention demonstrated the utility of exploring the expression of two potentially targetable immune checkpoint proteins – the programmed cell death protein 1 (PD-1) and its ligand, PD-L1 – in a substantial proportion of solid tumors using Caris Molecular Intelligence, the company's panomic, comprehensive tumor profiling service.